LOX and prostate cancer: If the THF-diols or LTX-diols modulate luteinizing-hormone–releasing hormone release via pathways related to NO synthase, phospholipase A (PLA), cyclooxygenase (COX), or lipoxygenase (LOX), the compounds may directly or indirectly control breast or prostate cancer growth and proliferation via modulation of gonadotropin release and/or ovarian or testicular steroidogenesis.